Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...

Massachusetts health insurers are effectively telling the drug companies that they may seek a rapidly growing customer base ...

Glucagon-like peptide-1 receptor agonists (GLP-1RA) drugs, such as Ozempic and Wegovy, are often referred to as "miracle ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

GLP-1 is a hormone that regulates blood sugar, appetite and digestion. A diet rich in high-fiber foods may help your body ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

This is only a glimpse of the data available to CivicScience clients. Discover more data. It’s safe to say that GLP-1 ...

GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...